Trial · NCT01468337
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Total Number of Severe Ocular Adverse Events Related to the Investigational Product | Week 48 | Adverse Events | NUMBER | |
| PRIMARY | Total Number of Ocular Adverse Events Related to Investigational Product | Week 48 | Adverse Events | NUMBER | |
| PRIMARY | Total Number of Severe Non-ocular Adverse Events Related to the Investigational Product | Week 48 | Adverse Events | NUMBER | |
| PRIMARY | Total Number of Non-ocular Adverse Events Related to the Investigational Product | Week 48 | Adverse Events | NUMBER | |
| PRIMARY | Number of Participants Who Withdrew From the Study | Week 48 | participants | NUMBER | |
| SECONDARY | Changes in Best-corrected Visual Acuity (BCVA) in the Study Eye at Week 2 Compared to Baseline | Baseline and Week 2 | ETDRS letters | MEAN | |
| SECONDARY | Changes in Best-corrected Visual Acuity (BCVA) in the Fellow Eye at Week 2 Compared to Baseline | Baseline and Week 2 | ETDRS letters | MEAN | |
| SECONDARY | Changes in Best-corrected Visual Acuity (BCVA) in the Study Eye at Week 48 Compared to Baseline | Baseline and Week 48 | ETDRS letters | MEAN | |
| SECONDARY | Changes in Best-corrected Visual Acuity (BCVA) in the Fellow Eye at Week 48 Compared to Baseline | Baseline and Week 48 | ETDRS letters | MEAN | |
| SECONDARY | Changes in the Maximum Subretinal Fluid Volume as Measured on Optical Coherence Tomography (OCT) at Week 2 Compared to Baseline | Baseline and Week 2 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in Central Retinal Thickness as Measured on Optical Coherence Tomography (OCT) at Week 2 Compared to Baseline | Baseline and Week 2 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in Leakage as Observed on Fluorescein Angiography (FA) at Week 2 Compared to Baseline | Baseline and Week 2 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in the Autofluorescence Patterns as Observed on Fundus Autofluorescence (FAF) Imaging at Week 2 Compared to Baseline | Baseline and Week 2 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in Mean Macular Sensitivity as Assessed by Microperimetry at Week 2 Compared to Baseline | Baseline and Week 2 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in the Maximum Subretinal Fluid Volume as Measured on Optical Coherence Tomography (OCT) at Week 48 Compared to Baseline | Baseline and Week 48 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in Central Retinal Thickness as Measured on Optical Coherence Tomography (OCT) at Week 48 Compared to Baseline | Baseline and Week 48 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in Leakage as Observed on Fluorescein Angiography (FA) at Week 48 Compared to Baseline | Baseline and Week 48 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in the Autofluorescence Patterns as Observed on Fundus Autofluorescence (FAF) Imaging at Week 48 Compared to Baseline | Baseline and Week 48 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. | ||
| SECONDARY | Changes in Mean Macular Sensitivity as Assessed by Microperimetry at Week 48 Compared to Baseline | Baseline and Week 48 | Due to lack of effect in other outcome measures, at investigator's discretion, data for this outcome measure was neither collected nor analyzed. As such, zero participants have data for this outcome. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01468337/outcomes